NeuroSense Historical Balance Sheet

NRSNW Stock

USD 0.23 0.30 56.60%

Trend analysis of NeuroSense Therapeutics Ltd balance sheet accounts such as Property Plant And Equipment Net of 287.4 K provides information on NeuroSense Therapeutics' total assets, liabilities, and equity, which is the actual value of NeuroSense Therapeutics to its prevalent stockholders. By breaking down trends over time using NeuroSense Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining NeuroSense Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NeuroSense Therapeutics is a good buy for the upcoming year.

NeuroSense Therapeutics Inventory

(3.14 Million)

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroSense Therapeutics Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy NeuroSense Stock please use our How to Invest in NeuroSense Therapeutics guide.

About NeuroSense Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of NeuroSense Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. NeuroSense Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of NeuroSense Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which NeuroSense currently owns. An asset can also be divided into two categories, current and non-current.

NeuroSense Therapeutics Balance Sheet Chart

At this time, NeuroSense Therapeutics' Liabilities And Stockholders Equity is fairly stable compared to the past year. Non Current Liabilities Total is likely to climb to about 1.9 M in 2025, whereas Net Debt is likely to drop (2.4 M) in 2025.

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net

Total Assets

Total assets refers to the total amount of NeuroSense Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NeuroSense Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on NeuroSense Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of NeuroSense Therapeutics Ltd are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from NeuroSense Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into NeuroSense Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroSense Therapeutics Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy NeuroSense Stock please use our How to Invest in NeuroSense Therapeutics guide.At this time, NeuroSense Therapeutics' Liabilities And Stockholders Equity is fairly stable compared to the past year. Non Current Liabilities Total is likely to climb to about 1.9 M in 2025, whereas Net Debt is likely to drop (2.4 M) in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	1.2M	1.9M	2.2M	2.3M
Total Assets	7.7M	3.2M	3.7M	5.3M

Other Current Liab Total Assets

NeuroSense Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Common Stock	Short Long Term Debt Total	Short Term Debt
Total Assets		0.5	0.43	0.68	0.5	-0.94	-0.51	0.33	0.95	0.4	-0.78	1.0	0.8	0.42	-0.48	0.91	0.64	0.54	0.68	0.49	1.0	0.81	-0.26	-0.45	0.21
Other Current Liab	0.5		1.0	-0.27	0.94	-0.33	-0.98	0.98	0.41	0.83	-0.91	0.46	0.85	0.98	-0.93	0.76	0.9	0.99	-0.27	0.95	0.48	-0.1	-0.75	-0.96	0.86
Total Current Liabilities	0.43	1.0		-0.35	0.92	-0.26	-0.97	0.99	0.34	0.81	-0.87	0.39	0.81	0.98	-0.92	0.7	0.88	0.98	-0.35	0.94	0.41	-0.18	-0.77	-0.95	0.89
Total Stockholder Equity	0.68	-0.27	-0.35		-0.18	-0.74	0.24	-0.46	0.67	-0.15	-0.12	0.71	0.19	-0.33	0.2	0.4	0.0	-0.24	1.0	-0.21	0.7	0.98	0.39	0.26	-0.49
Property Plant And Equipment Net	0.5	0.94	0.92	-0.18		-0.25	-0.95	0.89	0.3	0.94	-0.87	0.46	0.78	0.97	-0.99	0.76	0.9	0.88	-0.18	1.0	0.47	-0.05	-0.63	-0.99	0.73
Net Debt	-0.94	-0.33	-0.26	-0.74	-0.25		0.33	-0.16	-0.99	-0.17	0.65	-0.95	-0.72	-0.2	0.25	-0.8	-0.5	-0.41	-0.74	-0.25	-0.95	-0.86	0.08	0.22	-0.1
Retained Earnings	-0.51	-0.98	-0.97	0.24	-0.95	0.33		-0.95	-0.39	-0.89	0.91	-0.46	-0.87	-0.97	0.97	-0.79	-0.94	-0.96	0.24	-0.96	-0.48	0.07	0.62	0.97	-0.79
Accounts Payable	0.33	0.98	0.99	-0.46	0.89	-0.16	-0.95		0.25	0.77	-0.81	0.28	0.74	0.97	-0.89	0.62	0.83	0.97	-0.46	0.91	0.3	-0.29	-0.78	-0.92	0.91
Cash	0.95	0.41	0.34	0.67	0.3	-0.99	-0.39	0.25		0.18	-0.69	0.95	0.75	0.28	-0.3	0.82	0.52	0.49	0.67	0.31	0.95	0.81	-0.23	-0.27	0.2
Non Current Assets Total	0.4	0.83	0.81	-0.15	0.94	-0.17	-0.89	0.77	0.18		-0.8	0.36	0.74	0.89	-0.96	0.72	0.91	0.75	-0.15	0.93	0.37	-0.06	-0.38	-0.94	0.65
Non Currrent Assets Other	-0.78	-0.91	-0.87	-0.12	-0.87	0.65	0.91	-0.81	-0.69	-0.8		-0.75	-0.98	-0.86	0.88	-0.95	-0.96	-0.91	-0.12	-0.87	-0.76	-0.3	0.52	0.87	-0.7
Cash And Short Term Investments	1.0	0.46	0.39	0.71	0.46	-0.95	-0.46	0.28	0.95	0.36	-0.75		0.77	0.38	-0.44	0.89	0.6	0.51	0.71	0.45	1.0	0.83	-0.24	-0.4	0.18
Net Receivables	0.8	0.85	0.81	0.19	0.78	-0.72	-0.87	0.74	0.75	0.74	-0.98	0.77		0.77	-0.8	0.96	0.95	0.87	0.19	0.79	0.78	0.37	-0.43	-0.78	0.67
Common Stock Shares Outstanding	0.42	0.98	0.98	-0.33	0.97	-0.2	-0.97	0.97	0.28	0.89	-0.86	0.38	0.77		-0.97	0.7	0.88	0.94	-0.33	0.98	0.39	-0.18	-0.73	-0.99	0.84
Inventory	-0.48	-0.93	-0.92	0.2	-0.99	0.25	0.97	-0.89	-0.3	-0.96	0.88	-0.44	-0.8	-0.97		-0.77	-0.92	-0.88	0.2	-0.99	-0.46	0.06	0.55	0.99	-0.71
Other Current Assets	0.91	0.76	0.7	0.4	0.76	-0.8	-0.79	0.62	0.82	0.72	-0.95	0.89	0.96	0.7	-0.77		0.89	0.77	0.4	0.76	0.9	0.55	-0.37	-0.74	0.5
Other Stockholder Equity	0.64	0.9	0.88	0.0	0.9	-0.5	-0.94	0.83	0.52	0.91	-0.96	0.6	0.95	0.88	-0.92	0.89		0.89	0.0	0.9	0.62	0.16	-0.44	-0.91	0.74
Total Liab	0.54	0.99	0.98	-0.24	0.88	-0.41	-0.96	0.97	0.49	0.75	-0.91	0.51	0.87	0.94	-0.88	0.77	0.89		-0.24	0.9	0.52	-0.05	-0.75	-0.9	0.87
Net Invested Capital	0.68	-0.27	-0.35	1.0	-0.18	-0.74	0.24	-0.46	0.67	-0.15	-0.12	0.71	0.19	-0.33	0.2	0.4	0.0	-0.24		-0.21	0.7	0.98	0.39	0.26	-0.49
Property Plant And Equipment Gross	0.49	0.95	0.94	-0.21	1.0	-0.25	-0.96	0.91	0.31	0.93	-0.87	0.45	0.79	0.98	-0.99	0.76	0.9	0.9	-0.21		0.47	-0.07	-0.66	-1.0	0.76
Total Current Assets	1.0	0.48	0.41	0.7	0.47	-0.95	-0.48	0.3	0.95	0.37	-0.76	1.0	0.78	0.39	-0.46	0.9	0.62	0.52	0.7	0.47		0.82	-0.25	-0.42	0.19
Net Working Capital	0.81	-0.1	-0.18	0.98	-0.05	-0.86	0.07	-0.29	0.81	-0.06	-0.3	0.83	0.37	-0.18	0.06	0.55	0.16	-0.05	0.98	-0.07	0.82		0.27	0.12	-0.33
Common Stock	-0.26	-0.75	-0.77	0.39	-0.63	0.08	0.62	-0.78	-0.23	-0.38	0.52	-0.24	-0.43	-0.73	0.55	-0.37	-0.44	-0.75	0.39	-0.66	-0.25	0.27		0.63	-0.78
Short Long Term Debt Total	-0.45	-0.96	-0.95	0.26	-0.99	0.22	0.97	-0.92	-0.27	-0.94	0.87	-0.4	-0.78	-0.99	0.99	-0.74	-0.91	-0.9	0.26	-1.0	-0.42	0.12	0.63		-0.76
Short Term Debt	0.21	0.86	0.89	-0.49	0.73	-0.1	-0.79	0.91	0.2	0.65	-0.7	0.18	0.67	0.84	-0.71	0.5	0.74	0.87	-0.49	0.76	0.19	-0.33	-0.78	-0.76

Click cells to compare fundamentals

NeuroSense Therapeutics Account Relationship Matchups

NeuroSense Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	779K	11.4M	7.7M	3.2M	3.7M	5.3M
Other Current Liab	65K	558K	1.2M	1.9M	2.2M	2.3M
Total Current Liabilities	120K	597K	1.7M	3.5M	4.0M	4.2M
Total Stockholder Equity	659K	9.0M	5.6M	(1.9M)	(1.7M)	(1.6M)
Property Plant And Equipment Net	13K	19K	306K	238K	273.7K	287.4K
Net Debt	(699K)	(9.2M)	(3.3M)	(2.5M)	(2.2M)	(2.4M)
Retained Earnings	(4.4M)	(8.4M)	(20.8M)	(32.1M)	(28.9M)	(27.4M)
Accounts Payable	55K	39K	498K	1.5M	1.7M	1.8M
Cash	699K	11.1M	3.5M	2.6M	3.0M	4.1M
Non Current Assets Total	50K	19K	329K	260K	299K	154K
Cash And Short Term Investments	699K	11.1M	7.1M	2.6M	3.0M	4.9M
Net Receivables	30K	178K	131K	166K	190.9K	115.1K
Liabilities And Stockholders Equity	779K	11.4M	7.7M	3.2M	3.7M	5.3M
Other Current Assets	67.0	171K	160K	110K	126.5K	97.0K
Other Stockholder Equity	5.1M	17.5M	26.4M	30.2M	34.7M	18.0M
Total Liab	120K	2.4M	2.1M	5.1M	5.8M	6.1M
Net Invested Capital	659K	9.0M	5.6M	(1.9M)	(1.7M)	(1.6M)
Property Plant And Equipment Gross	16K	24K	323K	276K	317.4K	333.3K
Total Current Assets	729K	11.4M	7.4M	2.9M	3.4M	5.1M
Accumulated Other Comprehensive Income	5.1M	17.5M	26.4M	30.2M	34.7M	18.0M
Net Working Capital	609K	10.8M	5.7M	(543K)	(624.5K)	(593.2K)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for NeuroSense Stock Analysis

When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NeuroSense Historical Balance Sheet

NeuroSense Therapeutics Inventory

(3.14 Million)

About NeuroSense Balance Sheet Analysis

NeuroSense Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

NeuroSense Therapeutics balance sheet Correlations

NeuroSense Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NeuroSense Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for NeuroSense Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Net Invested Capital	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments

Short Long Term Debt Total	- 1.0	Property Plant And Equipment Gross
Property Plant And Equipment Gross	- 0.99	Inventory
Short Long Term Debt Total	- 0.99	Common Stock Shares Outstanding
Cash	- 0.99	Net Debt
Short Long Term Debt Total	- 0.99	Property Plant And Equipment Net
Inventory	- 0.99	Property Plant And Equipment Net